<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206218</url>
  </required_header>
  <id_info>
    <org_study_id>BREC-AGC</org_study_id>
    <nct_id>NCT01206218</nct_id>
  </id_info>
  <brief_title>Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer</brief_title>
  <acronym>BREC-AGC</acronym>
  <official_title>Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <brief_summary>
    <textblock>
      Evaluation of customized treatment according to BRCA1 assessment in patients with advanced
      gastric cancer
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FLOT Regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FLO Regimen or FLOT Regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLOT Regimen</intervention_name>
    <description>FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLO Regimen or FLOT Regimen</intervention_name>
    <description>FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent

          -  Female or male aged 18 years and over

          -  Histologic or cytologic confirmation of advanced gastric cancer

          -  Stage III-IV (AJCC 7th)

          -  ECOG: 0-2

          -  Have tumor sample that can be tested for BRCA1 mRNA expression

          -  Negative pregnancy test for women of childbearing potential

          -  Neutrophile granulocyte greater than 1.5×10^9/L

          -  Hemoglobin greater than 10g/dL

          -  Platelet greater than 100×10^9/L

          -  Serum bilirubin not greater than 1.5x upper limit of reference range (ULRR)

          -  ALT or AST not greater than 1.5x ULRR

          -  Creatinine clearance no less than 60ml/min

        Exclusion Criteria:

          -  Have at least another primary malignant tumor

          -  Active infection

          -  Chemotherapy with experimental drug within 3 weeks before the start of study therapy

          -  Women who are pregnant or breast feeding

          -  Weight loss greater 10% within 6 weeks before the start of study therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baorui Liu, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drum Tower Hospital, Nanjing University Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baorui Liu, MD, PHD</last_name>
    <phone>(86)13770621908</phone>
    <email>baoruiliu@nju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia Wei, MD, PHD</last_name>
    <phone>(86)13951785234</phone>
    <email>weijia01627@hotmail.com</email>
  </overall_contact_backup>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2010</study_first_submitted>
  <study_first_submitted_qc>September 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2010</study_first_posted>
  <last_update_submitted>September 20, 2010</last_update_submitted>
  <last_update_submitted_qc>September 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Baorui Liu</name_title>
    <organization>The Comprehensive Cancer Center of Drum Tower Hospital, Nanjing University Medical School</organization>
  </responsible_party>
  <keyword>Gastric Cancer, BRCA1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

